Trials / Terminated
TerminatedNCT04072016
Study of the Beacon Aqueous Microshunt in Patients With Refractory Glaucoma
The Beacon Study: A Prospective, Multicenter Study to Evaluate the Safety and Effectiveness of Beacon Aqueous Microshunt for Refractory Glaucoma
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- MicroOptx · Industry
- Sex
- All
- Age
- 22 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, multicenter, single-arm clinical study to evaluate the safety and effectiveness of Beacon Aqueous Microshunt in patients with refractory glaucoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Beacon Aqueous Microshunt | The Beacon Aqueous Microshunt (BAM) is an implantable device intended to reduce intraocular pressure (IOP) in patients with refractory glaucoma by shunting aqueous humor from the anterior chamber to the surface of the eye. |
Timeline
- Start date
- 2020-04-29
- Primary completion
- 2022-05-16
- Completion
- 2022-11-30
- First posted
- 2019-08-28
- Last updated
- 2023-01-10
Locations
4 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT04072016. Inclusion in this directory is not an endorsement.